Financial Results for the Quarter Ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parnax Lab reported a strong jump in Q3FY26 standalone profit of Rs 70.91 lakhs, up from Rs 15.78 lakhs a year ago, on revenue from operations more than doubling to Rs 270.82 lakhs from Rs 98.63 lakhs. On a consolidated basis (including subsidiary Naxpar Pharma), Q3 revenue rose to Rs 6,294.15 lakhs from Rs 4,021.61 lakhs, and net profit after minority interest climbed to Rs 271.47 lakhs (EPS Rs 2.37) from Rs 121.02 lakhs (EPS Rs 1.06). For the nine-month period, consolidated revenue grew about 29% to Rs 17,891.89 lakhs with net profit up nearly 12% to Rs 960.03 lakhs. The board booked an exceptional expense of Rs 113.80 lakhs (consolidated) related to the new Labour Codes gratuity impact. The board also approved the appointment of an Independent Director at its February 13, 2026 meeting.
Strong Q3 earnings growth, especially at the consolidated level driven by subsidiary Naxpar Pharma, is a positive signal for shareholders. The Labour Codes-related one-time charge modestly trims headline profit but does not change the underlying growth story.